Endogena Therapeutics, Inc.’s Post

💊 𝐀𝐝𝐝𝐫𝐞𝐬𝐬𝐢𝐧𝐠 𝐭𝐡𝐞 𝐆𝐥𝐨𝐛𝐚𝐥 𝐀𝐌𝐑 𝐓𝐡𝐫𝐞𝐚𝐭 - 𝐀 𝐂𝐚𝐥𝐥 𝐭𝐨 𝐂𝐨𝐥𝐥𝐞𝐜𝐭𝐢𝐯𝐞 𝐀𝐜𝐭𝐢𝐨𝐧 👩🔬 I am so thrilled to release Cavenagh Health's latest white paper which focuses on 𝐀𝐧𝐭𝐢𝐦𝐢𝐜𝐫𝐨𝐛𝐢𝐚𝐥 𝐑𝐞𝐬𝐢𝐬𝐭𝐚𝐧𝐜𝐞 (𝐀𝐌𝐑)! Guillermo Tramontin and I have collaborated with the amazing Mercedes Gonzalez Moreno from INCATEurope and Gregorio Iraola from Kinzbio to discuss the state of the art in the AMR space, including the role of Bacteriophages and Microbiome therapeutics as alternative to traditional small molecules antibiotics.  We are extremely proud for hosting the contributions from key players such as Nel Moore, Tim Mak 添 PhD MBA and Patrick Guye from Trilliome GmbH, Ken Blount and Tom Willard, MBA from Ferring Pharmaceuticals, Martin Heidecker from the AMR Action Fund, Shionogi Europe and MENARINI Group.   This white paper is a collection of perspectives from 𝐛𝐢𝐨𝐭𝐞𝐜𝐡𝐬, 𝐢𝐧𝐯𝐞𝐬𝐭𝐨𝐫𝐬, and 𝐩𝐡𝐚𝐫𝐦𝐚 companies - intended to serve as a wake-up call for our society and for the key actors who can make a difference.  In a true #OneHealthApproach style, it's essential we find the way forward together - but we need to act 𝒏𝒐𝒘 to avoid what is poised to be the century's leading threat.     These are only a few of the themes we cover in the document: 💡 What's happening in the Preclinical/Clinical pipeline? 💡 What are the challenges of clinical trials? 💡 How does the financial landscape of AMR R&D look? 💡 What are investors looking for?  💡 How do Pharma companies perceive the AMR space?   💡 What are the current Push/Pull initiatives?  🙏 Let's unite our efforts in raising awareness and fuel the conversation.  Join us in Basel for the 8th #AMRConference this March and let's make an impact together. Elcin Barker Ergun, Najy Alsayed MD, M.Sc., Helmut Kessmann,Simona Falciai, Huw Tippett, Jessica Smith, Hollie Ruda, SomX Link to download the white paper: https://lnkd.in/gmznB-dZ #amr #innovation #antibioticresistance #biotech #healthcareinnovation #bacteriophages #microbiome

Exciting News from COLOTAN 4th Symposium!    On January 10th, join Prof. Amin Rostami-Hodjegan, CSO of Certara, in Cork, Ireland, for the annual Symposium of this influential EU research network. He'll delve into the intricacies of Crohn's Disease, shedding light on precision dosing and its profound impact.   Amin will explore the pursuit of optimal dosing in orphan disease populations, emphasizing the crucial role of virtual trials powered by Physiologically Based Pharmacokinetics (PBPK) in tailoring individual drug dosages. These trials tackle challenges in drug development for orphan diseases and subpopulations with comorbidities. At Certara, our research teams are committed to investing in platforms that unlock the transformative potential of virtual clinical studies. Discover more about COLOTAN and explore the lineup of presentations at: https://ow.ly/1lbL50QoOvf. For deeper insights into PBPK, visit https://lnkd.in/eStKcKZ3.   #COLOTAN4thSymposium #PrecisionDosing #PBPK #CrohnsDisease #Bioequivalence #InnovationInMedicine #ClinicalResearch

Iveric Bio, An Astellas Company presented details on our GATHER2 2-year data at #AAO2023! We were delighted to discuss our treatment for patients with geographic atrophy.  Learn more about the presentation:  https://lnkd.in/g92kcpVr #GeographicAtrophy

Registration is now open for our industry symposium 'Accelerating CF Research: Strategies for rapidly progressing your science to clinical impact', organised by Cystic Fibrosis Trust with support from LifeArc. Please register here to secure your place. https://lnkd.in/eDpmnCJH Places are limited and early registration is highly recommended to avoid disappointment. Date: Wednesday 5 June Time: 10.30am-1.30pm, including a networking lunch Location: Glasgow Science Centre, Pacific Quay, G51 1EA At this event you will find out more about: Uncovering funding opportunities: Learn how to secure funding for pre-clinical proof of principle studies. Accelerating your research: Find out how we can deliver research closer to patients and gain access to lived experience insights. Learn how to set up and deliver clinical trials through our Clinical Trials Accelerator Platform (CTAP). Diving into data-driven insights: Explore the power of data within the UK CF Registry to inform clinical trial design and support pharmacovigilance, pharmacoepidemiology and real-world evidence studies. Tapping into support: Discover how Cystic Fibrosis Trust, Medicines Discovery Catapult and LifeArc can work in partnership with you, providing you with resources, funding and support through the CF AMR Syndicate. We look forward to seeing you there! And please do share with anyone who might be interested.

Check out this exciting series!

Don't forget to join today at 5pm CEST to the final webinar of the Nocturnal Scratch series. Today an exciting panel including EMA and FDA will be discussing the validation and adoption of the digital measurements of nocturnal scratch. My collegue John Batchelor will also be sharing how stack model was used during the EMA pilot to facilitate the engagement between the regulators and the applicant team. Sign up if you haven't yet! #webinar #digitalmesures #collaboration DEEP Measures Digital Medicine Society (DiMe)

The Target to Patient T2P 2024 conference at Wellcome Genome Campus on April 29/30 is now open for registration with great early bird discounts and a fantastic line up of speakers (full list is here https://lnkd.in/eFmPy-hJ) https://lnkd.in/eVRk2nyF David Hulcoop - thank you for agreeing to speak at this exciting conference. We are looking forward to hearing your perspective on how Open Targets is helping to transform how we look for new targets for drug discovery. #drugdiscovery #drugdevelopment #drugdesign #opentargets #genetics #genomics

What does it take to create Europe's next globally leading biotech ecosystem, covering every step from groundbreaking research to successful commercialisation? This was the leading question at this year’s fireside panel discussion at the #DRFZBerlinSymposium2024.     Key takeaways from the panel discussion: Strong Consensus: Europe has the huge potential conducting groundbreaking research.      Issue: A significant gap exists in translating research from the lab to the clinic, especially due to complex regulatory frameworks.      Recommendation: Policymakers must simplify regulatory frameworks and provide clearer guidance to accelerate the path of new therapies to patients.     Thanks for this great exchange between our Joachim von Arnim and Eicke Latz (German Rheumatology Research Center) | Stefan Miltenyi (Miltenyi Biotec) | Luke O'Neill (Trinity College Dublin) | Jan-Philipp Kruse (Bayer) | Dr. Thorsten Lambertus (DEEP - ESMT Berlin) as well as moderator Marco Janezic (Blue Ribbon Partners)     #TissueTherapeutics #Cellbricks #Charité #MaxPlanckSociety #Ecosystem 

CDRC, Critical Path Institute (C-Path), and CURE ID team members will be traveling to Barcelona to attend the International Drug Repurposing Conference 2024 (#iDR24): Bridging boundaries for Innovative Drug Repurposing. Join them on 6-7 March 2024 at Sant Pau Art Nouveau World Heritage Site Sant for #iDR24, uniting key players in drug repurposing. Co-organized by REMEDi4ALL Consortium, Beacon for Rare Diseases, and MeRIT, the conference showcases how patient communities, researchers, industry, and health authorities can benefit from cutting-edge drug repurposing. The agenda follows 3 topical paths in parallel: · Cancer path · Rare diseases path · Methodologies path Explore cutting-edge insights, discuss challenges, and engage with experts. Find out more about the speakers, location, ticket prices and more here: https://lnkd.in/eRtYcAmZ Smith Heavner, PhD, RN| Marco Schito| Heather Stone| Shira Strongin| Keyla Tumas| REMEDi4ALL| Beacon for Rare Diseases| #REMEDi4ALL #Beacon #MeRIT #drugrepurposing #patientadvocacy

Last week, Kuros Biosciences sponsored a presentation at Base to Summit entitled 'Favorable Results of MagnetOs as Standalone Alternative to Autograft in a Prospective, Multi-center, Randomized, Intra-patient Controlled Trial.' Pictured below are images of Dr. Robert Eastlack presenting, featuring a slide of a case report from the investigator-led, level 1 clinical trial. For more information about Kuros or this level 1 clinical trial, click here to meet with one of our experts → https://lnkd.in/gTV-zSvJ #spine #basetosummit #kurosbiosciences